Alexandra K. Golant, MD

Alexandra K. Golant, MD, and Mona Shahriari, MD, share thoughts on newer topical treatments as well as the role of topical treatments in managing plaque psoriasis.

Expert dermatologists discuss approaches to treatment selection for patients with plaque psoriasis, taking into account the impact of the therapy on quality of life.

Mona Shahriari, MD, comments on plaque psoriasis in skin of color populations, as well as the importance of shared decision-making between patient and dermatologist.

Alexandra K. Golant, MD, and Mona Shahriari, MD, provide an overview of the pathophysiology of plaque psoriasis, commenting on the many comorbidities that stem from this disease.

Brett King, M.D, Ph.D and Alexandra Golant, M.D summarize their thoughts on optimizing treatment outcomes for patients suffering from atopic dermatitis with the JAK inhibitor class.

Experts in atopic disease management review the efficacy and safety data of the JAK inhibitor class, highlighting the importance of time to treatment response and itch reduction.

Drs Alexandra Golant and Brett King discuss the role that atopic disease severity and treatment resistance play in the selection of oral vs systemic treatment for their patients.

Brett King, M.D, Ph.D and Alexandra Golant M.D comment on their considerations on the management of patients suffering from atopic dermatitis, highlighting the importance of body surface area and patient preference in treatment selection.

In part 5 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

In part 4 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

In part 3 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

In part 2 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

In part 1 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.